ArticleAmerican journal of translational research2025
Study on the expression of S100A4 and HMGA1 in endometrial carcinoma and their correlation with metastasis.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- S100A4/FSP1: A Prognostic Marker and a Promising Target for Antitumor Therapy.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the relationship between the expression of S100 calcium-binding protein A4 (S100A4), high mobility group protein A1 (HMGA1) and clinicopathological features, as well as postoperative recurrence and metastasis in endometrial cancer patients.
methodsSixty endometrial cancer patients (observation group) were selected for this study, along with 40 patients who underwent hysterectomy for benign diseases (control group) during the same period. Surgically resected endometrial cancer tissues and normal endometrial tissues were collected. The expression levels of HMGA1 and S100A4 mRNA were detected using real-time fluorescence quantitative polymerase chain reaction (qPCR), while the HMGA1 and S100A4 protein expression was detected by immunohistochemistry and Western blot. Clinical data including tumor diameter, histological grading, distant metastasis, lymph node metastasis, depth of infiltration, lymphovascular infiltration, and International Federation of Gynecology and Obstetrics (FIGO) staging were collected. Patients with endometrial cancer were categorized into a non-recurrent-metastasis group and a recurrent-metastasis group based on their one-year postoperative follow-up results.
resultsThe mRNA and protein expression levels of HMGA1 and S100A4 were significantly higher in endometrial cancer tissues compared to normal endometrial tissues (all P<0.05). Protein expression of HMGA1 and S100A4 was significantly associated with tumor diameters, distant metastases, lymph node metastases, depth of infiltration and lymphovascular infiltration. Specifically, endometrial cancer patients with tumor diameters >2 cm, distant metastases, lymph node metastases, infiltration depths beyond ½ myometrium, and higher lymphovascular infiltration rates, exhibited significantly higher positive expression of HMGA1 and S100A4 (all P<0.05). In the recurrent-metastasis group, HMGA1 and S100A4 protein expression levels were significantly higher than those in the no recurrent-metastasis group (all P<0.05). Significant differences were found between the two groups in terms of tumor diameter, histological grading, infiltration depth, lymphovascular infiltration and FIGO stage (all P<0.01). Multifactorial logistic regression analysis identified HMGA1 and S100A4 protein expression, infiltration depth, lymphovascular infiltration and FIGO stage as independent risk factors for postoperative recurrence and metastasis in endometrial cancer patients after surgery. Receiver operator characteristic (ROC) curves showed that HMGA1 and S100A4 protein expression had high predictive value for postoperative recurrence and metastasis in endometrial cancer patients (all P<0.05).
conclusionThe increased positive expression of HMGA1 and S100A4 in the endometrial cancer tissues is closely related to the clinicopathological features and postoperative recurrence and metastasis. HMGA1 and S100A4 have significant predictive value for assessing the likelihood of postoperative recurrence and metastasis in endometrial cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.